Analysis of protein prenylation in vitro and in vivo using functionalized phosphoisoprenoids
- PMID: 21104984
- DOI: 10.1002/0471140864.ps1403s62
Analysis of protein prenylation in vitro and in vivo using functionalized phosphoisoprenoids
Abstract
Post-translational modifications (PTMs) expand the number of protein isoforms in eukaryotic proteome by orders of magnitude. Protein modification with isoprenoid lipids is a common PTM affecting hundreds of proteins controlling the transport of information and materials into, through, and out of the eukaryotic cell. In this modification, a soluble phosphoisoprenoid such as farnesyl (C15) or geranylgeranyl (C20) pyrophosphate moiety is recruited by one of three protein prenyltransferases to covalently modify a C-terminal cysteine(s) in a target protein. The three mammalian prenyltransferases are farnesyltransferase (FTase), geranylgeranyltransferase type I (GGTase I), and Rab geranylgeranyl transferase (also termed geranylgeranyltransferase type II - GGTase II). In this unit, synthetic isoprenoids conjugated to either a fluorophore or biotin group are used to assay the activity of protein prenyltransferases in vitro or to affinity tag prenylatable proteins in cell lysates. These protocols and their modifications can be used to study the mechanisms of protein prenylation, identify prenylation targets, and characterize inhibitors of protein prenyltransferases in vitro and in vivo.
© 2010 by John Wiley & Sons, Inc.
Similar articles
-
Identification and specificity profiling of protein prenyltransferase inhibitors using new fluorescent phosphoisoprenoids.J Am Chem Soc. 2006 Mar 8;128(9):2822-35. doi: 10.1021/ja052196e. J Am Chem Soc. 2006. PMID: 16506760
-
Phosphoisoprenoid binding specificity of geranylgeranyltransferase type II.Biochemistry. 2000 Oct 3;39(39):12043-52. doi: 10.1021/bi000835m. Biochemistry. 2000. PMID: 11009619
-
Conversion of protein farnesyltransferase to a geranylgeranyltransferase.Biochemistry. 2006 Aug 15;45(32):9746-55. doi: 10.1021/bi060295e. Biochemistry. 2006. PMID: 16893176
-
Protein Geranylgeranyltransferase Type 1 as a Target in Cancer.Curr Cancer Drug Targets. 2016;16(7):563-71. doi: 10.2174/1568009616666151203224603. Curr Cancer Drug Targets. 2016. PMID: 26648485 Review.
-
Protein Prenyltransferases and Their Inhibitors: Structural and Functional Characterization.Int J Mol Sci. 2022 May 12;23(10):5424. doi: 10.3390/ijms23105424. Int J Mol Sci. 2022. PMID: 35628237 Free PMC article. Review.
Cited by
-
Proof of concept for AAV2/5-mediated gene therapy in iPSC-derived retinal pigment epithelium of a choroideremia patient.Mol Ther Methods Clin Dev. 2014 Apr 2;1:14011. doi: 10.1038/mtm.2014.11. eCollection 2014. Mol Ther Methods Clin Dev. 2014. PMID: 26015956 Free PMC article.
-
Towards the systematic mapping and engineering of the protein prenylation machinery in Saccharomyces cerevisiae.PLoS One. 2015 Mar 13;10(3):e0120716. doi: 10.1371/journal.pone.0120716. eCollection 2015. PLoS One. 2015. PMID: 25768003 Free PMC article.
-
Evaluation of CRISPR/Cas9 exon-skipping vector for choroideremia using human induced pluripotent stem cell-derived RPE.J Gene Med. 2023 Feb;25(2):e3464. doi: 10.1002/jgm.3464. Epub 2022 Dec 4. J Gene Med. 2023. PMID: 36413603 Free PMC article.
-
Reduced Retinal Pigment Epithelial Autophagy Due to Loss of Rab12 Prenylation in a Human iPSC-RPE Model of Choroideremia.Cells. 2024 Jun 19;13(12):1068. doi: 10.3390/cells13121068. Cells. 2024. PMID: 38920696 Free PMC article.
-
PARIS farnesylation prevents neurodegeneration in models of Parkinson's disease.Sci Transl Med. 2021 Jul 28;13(604):eaax8891. doi: 10.1126/scitranslmed.aax8891. Sci Transl Med. 2021. PMID: 34321320 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous